CALC Stock Analysis: Buy, Sell, or Hold?
CALC - CalciMedica, Inc. Common Stock
$1.06
0.21 (24.62%)
▲
5d:
+29.74%
30d:
+70.31%
90d:
+45.8%
WAIT
LOW Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When CALC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CALC is 30.9% above its trading range ($0.81). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CALC is 30.9% above its trading range ($0.81). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CALC is currently trading at $1.06, which is considered extended relative to its 30-day fair value range of $0.57 to $0.81.
Technical Outlook: Technically, CALC is in a downtrend. Immediate support is located at $0.61, while resistance sits at $1.14. The stock is showing strong short-term momentum, up 24.6% recently.
Market Sentiment: CALC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.33 (+874.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CALC is in a downtrend. Immediate support is located at $0.61, while resistance sits at $1.14. The stock is showing strong short-term momentum, up 24.6% recently.
Market Sentiment: CALC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.33 (+874.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.57 -
$0.81
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+30.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+24.6%)
- BULLISH: Trading 874.8% below Wall St target ($10.33)
- WARNING: Recommendation downgraded due to 30.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.81
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$1.14
Current Trend
Downtrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.54
Wall Street Target
$10.33
(+874.8%)
Share & Embed Analysis
Last updated: June 06, 2026 5:30 AM ET
Data refreshes hourly during market hours. Next update: 6:30 AM
Data refreshes hourly during market hours. Next update: 6:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CALC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 53 HOLD |
